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ORIGINAL ARTICLE
Deficiency of tumour necrosis factor-related
apoptosis-inducing ligand exacerbates lung injury
and fibrosis
Emmet E McGrath,1 Allan Lawrie,2 Helen M Marriott,1 Paul Mercer,3
Simon S Cross,4 Nadine Arnold,2 Vanessa Singleton,1 Alfred A R Thompson,1
Sarah R Walmsley,1 Stephen A Renshaw,1 Ian Sabroe,1 Rachel C Chambers,3
David H Dockrell,2 Moira K B Whyte1
ABSTRACT
Background The death receptor ligand tumour necrosis
factor-related apoptosis-inducing ligand (TRAIL) shows
considerable clinical promise as a therapeutic agent.
TRAIL induces leukocyte apoptosis, reducing acute
inflammatory responses in the lung. It is not known
whether TRAIL modifies chronic lung injury or whether
TRAIL has a role in human idiopathic pulmonary fibrosis
(IPF). We therefore explored the capacity of TRAIL to
modify chronic inflammatory lung injury and studied TRAIL
expression in patients with IPF.
Methods TRAIL/ and wild-type mice were instilled
with bleomycin and inflammation assessed at various
time points by bronchoalveolar lavage and histology.
Collagen deposition was measured by tissue
hydroxyproline content. TRAIL expression in human IPF
lung samples was assessed by immunohistochemistry
and peripheral blood TRAIL measured by ELISA.
Results TRAIL/ mice had an exaggerated delayed
inflammatory response to bleomycin, with increased
neutrophil numbers (mean 3.1960.8 wild type vs
11.565.43104 TRAIL/, p<0.0001), reduced
neutrophil apoptosis (5.4261.6% wild type vs
2.4760.5% TRAIL/, p¼0.0003) and increased
collagen (3.4560.2 wild type vs 5.861.3 mg TRAIL/,
p¼0.005). Immunohistochemical analysis showed
induction of TRAIL in bleomycin-treated wild-type mice.
Patients with IPF demonstrated lower levels of TRAIL
expression than in control lung biopsies and their serum
levels of TRAIL were significantly lower compared with
matched controls (38.169.6 controls vs 32.367.2 pg/ml
patients with IPF, p¼0.002).
Conclusion These data suggest TRAIL may exert
beneficial, anti-inflammatory actions in chronic pulmonary
inflammation in murine models and that these
mechanisms may be compromised in human IPF.
INTRODUCTION
Idiopathic pulmonary ﬁbrosis (IPF) is a chronic
scarring disease of the lung of uncertain pathogen-
esis and to date no therapy has convincingly
improved survival or modiﬁed clinical course.1 IPF is
a heterogeneous condition both in terms of clinical
course and pathological appearance. This suggests it
may be initiated by different forms of lung injury
and alveolar epithelial injury followed by aberrant
repair is currently regarded as a central pathogenic
mechanism.2 The role of inﬂammation, and partic-
ularly of neutrophils, in IPF is controversial but
neutrophilic alveolitis is a frequent feature of the
disease.3 4 Moreover, higher neutrophil counts in
bronchoalveolar lavage (BAL) are associated with
more rapid disease progression and with worse lung
function.5 6 Neutrophilic inﬂammation is also
a component of experimental models of IPF,
including bleomycin-induced lung injury in mice.7 8
Tumour necrosis factor-related apoptosis-
inducing ligand (TRAIL) has important roles in
regulating cell survival, particularly of immune cell
populations. TRAIL is a type II membrane protein
that is principally expressed by leucocytes, including
monocytes, macrophages, lymphoid cells and
neutrophils.9 In humans, TRAIL interacts with four
membrane receptors belonging to the TNF receptor
family. TRAIL receptor 1 (TRAIL-R1) andTRAIL-R2
have cytoplasmic death domains, and can activate
caspases and nuclear factor kB (NFkB). The receptors
TRAIL-R3 and TRAIL-R4 have truncated death
domains and do not activate caspases; they are
usually described as decoy receptors but may acti-
vate NFkB. A soluble decoy receptor for TRAIL,
osteoprotegerin (OPG), is also described. Mice have
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a single TRAIL death receptor, which shares 79% sequence
homology with human TRAIL-R2, together with two decoy
receptors.10 The clinical promise of TRAIL as an agentwithwhich
to manipulate apoptosis is emphasised by its use in phase I and II
studies in cancer therapy.11
We previously showed exogenous TRAIL can accelerate
apoptosis of neutrophils, a key cellular process for resolving
inﬂammation in vivo.12 13 TRAIL is implicated in the elimina-
tion of senescent neutrophils from the human circulation.14 Our
recent data in a murine model of acute lung injury show TRAIL
regulates neutrophil lifespan at sites of inﬂammation.15 There is
little data on roles of TRAIL in chronic inﬂammation. TRAIL
can, however, modify ﬁbrosis, since TRAIL treatment of mice
has been shown to promote resolution of hepatic ﬁbrosis and,
importantly, there is evidence TRAIL may directly induce
apoptosis of primary lung ﬁbroblasts.16 17
Because of these dual effects upon neutrophils and ﬁbroblasts
we hypothesised TRAIL may regulate chronic inﬂammation in
the lung, modifying both the inﬂammatory and ﬁbroproliferative
components of this condition, and play a role in human IPF.
MATERIALS AND METHODS
Animals
TRAIL/ mice on a C57/BL6 background were a kind gift from
Amgen (Seattle, Washington, USA). All procedures were
approved by the University of Shefﬁeld Ethics Committee and
were performed in accordance with the Home Ofﬁce Animal
(Scientiﬁc Procedures) Act 1986.
Human subjects
All lung tissue was supplied by the Cambridge Tissue Bank with
approval from the Papworth Hospital Ethics Committee, with
further details in the online supplement. Serum samples were
collected from 31 patients with IPF. Controls were age and sex
matched to patients with IPF and were recruited via the
patient’s family physician who conﬁrmed they did not have
a diagnosis of interstitial lung disease. Clinical data, including
pulmonary function tests, are provided in the online supple-
ment. These studies were performed with the approval of the
South Shefﬁeld Research Ethics Committee.
Bleomycin model of lung injury
Female mice were used between 8 and 12 weeks of age, in accor-
dance with the UK Home Ofﬁce Animals (Scientiﬁc Procedures)
Act, 1986. Clinical-grade bleomycin (Nippon Kayaku, Slough,
UK) 1 mg/kg bodyweight in 30 ml of saline, or an equal volume of
saline as a control, was administered by single intratracheal
injection into a surgically exposed trachea under anaesthesia.
Bronchoalveolar lavage
Following BAL a haemocytometer total cell count was
performed and differential cell counts calculated from cytospin
preparations (Cytospin 3; Thermo Shandon, Runcorn, UK)
stained with Diff-Quik and assessed by blinded reviewers.
Assessment of neutrophil apoptosis
The proportion of apoptotic neutrophils was determined by
blinded reviewers, counting duplicate cytospins stained by Diff-
Quik (>300 cells per slide).
Measurement of total lung collagen
Total lung collagen was calculated by measuring hydroxyproline
content in aliquots of pulverised lung. Details are given in the
online supplement.
Preparation of lung tissue for histological studies
Unlavaged lungs were insufﬂated with 4% paraformaldehyde in
phosphate-buffered saline (PBS) at a pressure of 20 cm H2O,
followed by removal of the heart and inﬂated lungs en bloc and
immersion for 4 h in fresh ﬁxative. Subsequently lungs were
transferred into 15% sucrose in PBS and left overnight at 48C,
before transfer to 70% ethanol.
Masson’s trichrome staining
Unlavaged lungs were formalin ﬁxed, processed and embedded
in parafﬁn wax blocks. Sections of lung tissue were stained as
described in the online data supplement.
Immunohistochemistry
Staining with speciﬁc antibodies and TUNEL staining was
performed as detailed in the online data supplement.
ELISAs
ELISAs for TRAIL and OPG were from R&D Systems
(Abingdon, UK) and performed according to the manufacturer ’s
instructions.
Statistical analysis
Unless otherwise stated, results were analysed using a one-way or
two-way analysis of variance as appropriate, followed by a
Bonferroni’s post-test for multiple comparisons. Patient and
control data for serum TRAIL and OPG levels were compared
using two-tail paired t-tests. Correlations between serum TRAIL
levels and total diffusing capacity of the lung for carbonmonoxide
(TLco) or survival were assessed using Pearson’s correlation
coefﬁcient. Results were considered signiﬁcant if p<0.05.
RESULTS
Bleomycin-mediated pulmonary inflammation is enhanced in
TRAIL-deficient mice
The composition of BAL was assessed at time points up to
23 days following bleomycin administration. Bleomycin instilla-
tion resulted in inﬂammatory cell recruitment into the lungs of
challenged mice. BAL ﬂuid from control mice (PBS instilled)
consisted overwhelmingly of alveolar macrophages and
contained <0.13105 neutrophils at all time points in wild-type
and TRAIL/ strains (data not shown). There was an enhanced
inﬂammatory response in TRAIL/ compared with wild-type
mice, with signiﬁcantly increased total and percentage neutrophil
counts at day 7 following bleomycin instillation (mean
3.1960.83104 in wild-type vs 11.565.43104 in TRAIL/ mice,
p<0.0001; mean 2.8761.0% in wild-type vs 8.2561.3% neutro-
phils in TRAIL/ mice, p<0.0001) (ﬁgure 1A,B). Macrophages
(as total or percentage count) were not signiﬁcantly different
between the groups ofmice (ﬁgure 1C,D) but TRAIL/mice also
had a signiﬁcant increase in total lymphocytes at day 7 when
comparedwithwild-typemice (mean 7.3262.83104 inwild-type
vs 14.664.83104 in TRAIL/ mice, p¼0.035) (ﬁgure 1E). To
characterise the neutrophilic inﬂammation in more detail, we
performed additional time points at day 5 and 10 and conﬁrmed
peak neutrophil counts were detected at day 7 (data not shown).
Lymphocyte numbers also peaked at day 7 and were predomi-
nantly CD3+ as opposed to CD19+ cells (data not shown).
TRAIL-deficient mice have reduced apoptosis following
bleomycin-induced lung injury
TUNEL staining of day 23 lung sections from both wild-type
and TRAIL/ mice revealed signiﬁcantly fewer apoptotic cells
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in TRAIL/mice (mean 46.4625.1 cells/high-power ﬁeld (HPF)
in wild-type vs 8.9066.30 cells/HPF in TRAIL/ mice,
p<0.0001) (ﬁgure 2). The majority of apoptotic events seen in
wild-type mice were in areas with numerous inﬂuxing inﬂam-
matory cells (ﬁgure 2A). Very few such events were seen in
TRAIL/ mice, despite the presence of inﬂammatory inﬁltrates
(ﬁgure 2B). That differences in rates of apoptosis in the
inﬂammatory cell inﬁltrate explained the differences in numbers
of TUNEL-positive events was apparent by analysing the
numbers of apoptotic cells in BAL (ﬁgure 3). The proportion of
the neutrophil BAL population after bleomycin instillation that
had the microscopic appearances of apoptosis was <2% in BAL
from both wild-type and TRAIL/mice at day 3. This increased
as neutrophil numbers peaked at day 7 and then decreased (ﬁgure
3A). At later time points there was a signiﬁcantly lower
proportion of apoptotic neutrophils in the TRAIL/ mice, for
example, mean 5.4261.6% in wild-type vs 2.4760.5% in
TRAIL/ mice at day 7, p¼0.0003. This suggested reduced
apoptosis was contributing to the greater neutrophil numbers in
BAL of TRAIL/ mice. Despite the greater neutrophil numbers
in TRAIL/ mice, these mice also showed fewer absolute
numbers of apoptotic neutrophils than their wild-type
counterparts (ﬁgure 3B).
TRAIL-deficient mice have increased total lung collagen
The effect of TRAIL deﬁciency on total lung collagen accumu-
lation, 16 days after intratracheal administration of bleomycin
or saline, is shown in ﬁgure 4. This time point has previously
identiﬁed signiﬁcant differences in ﬁbro-proliferative responses
to bleomycin.18 TRAIL/ and wild-type mice demonstrated no
signiﬁcant difference in lung collagen levels after saline chal-
lenge. Lung collagen accumulation was signiﬁcantly increased in
bleomycin-instilled wild-type mice compared with saline control
(mean 2.0860.60 mg with saline treatment vs 3.4660.30 mg
with bleomycin, p¼0.0033) and was of at least equivalent
magnitude to previous studies using the same experimental
protocol.18 In comparison to wild-type mice there was a signiﬁ-
cantly greater increase in collagen accumulation following
bleomycin treatment in TRAIL/ mice (mean 3.4660.3 mg in
wild-type vs 5.861.3 mg in TRAIL/ mice, p¼0.005).
TRAIL immunolocalisation following bleomycin-induced lung
injury
Immunohistochemical examination of TRAIL expression in the
lung was performed at key time points in wild-type mice, with
TRAIL/ mice acting as controls. In wild-type animals
receiving saline intratracheally, TRAIL staining of the bronchial
epithelium was observed, together with some staining in alve-
olar type 2 pneumocytes, in keeping with previous studies.19
Following bleomycin administration, no speciﬁc TRAIL immu-
nostaining was detected in TRAIL/ mice (ﬁgure 5A), while in
wild-type mice staining was seen in the bronchial and alveolar
epithelium and also in well deﬁned groups of cells adjacent to
the bronchial epithelium and in cells in the alveolar air spaces
Figure 1 Differential leucocyte counts
in bronchoalveolar lavage (BAL) fluid
following intratracheal administration of
bleomycin in wild-type and tumour
necrosis factor-related apoptosis-
inducing ligand (TRAIL)-deficient mice.
Differential leucocyte counts were
obtained from cytocentrifuge
preparations of BAL fluid lavaged from
the lungs at time points up to 23 days.
(A,D) Total and percentage neutrophil
counts (mean 6 SEM of at least five
independent experiments) for each time
point were obtained by multiplying the
differential count by the total leucocyte
number obtained from haemocytometer
counts for wild-type (solid line) and
TRAIL/ mice (dashed line). (B,E)
Total and percentage macrophage
counts for each time point. (C,F) Total
and percentage lymphocyte counts for
each time point. Both absolute
(***p<0.0001) and percentage
(*p<0.0001) neutrophil counts were
increased in TRAIL/ mice compared
with wild-type mice at day 7, as were
total lymphocyte counts (p¼0.035).
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(ﬁgure 5BeD). These positively staining cells were identiﬁed as
bronchus-associated lymphoid tissue and alveolar macrophages,
as illustrated by staining with anti-CD3 and anti-galectin-3
antibodies respectively (online supplement).
Immunohistochemical expression of TRAIL in human IPF
To examine the potential role of TRAIL in human ﬁbrotic lung
disease, we examined TRAIL expression in human lung tissue
specimens by immunohistochemistry. In lung sections from
control patients there was positive staining for TRAIL associ-
ated with resident alveolar macrophages and in the epithelium
(ﬁgure 6A,B), in keeping with ﬁndings in unchallenged wild-type
mice (ﬁgure 5 and Weckmann et al19). In lung tissue obtained
from patients with established IPF, TRAIL staining was detected
in areas of relatively normal lung, both in alveolar macrophages
and epithelial cells (ﬁgure 6C,D). In areas of dense ﬁbrosis,
however, there was little staining either of alveolar macrophages
or of lymphoid tissue with variable but generally low-level
staining of the respiratory epithelium (ﬁgure 6E,F).
Serum TRAIL is reduced in patients with IPF compared with
controls
The soluble form of TRAIL is normally present in serum and can
be detected by ELISA, as can its soluble receptor, OPG.9 20
Absolute serum levels of TRAIL were reduced in patients with
IPF relative to their matched controls (p¼0.002, ﬁgure 7A)
although OPG levels were not signiﬁcantly altered (p¼0.230,
ﬁgure 7B). The ratio of OPG:TRAIL was signiﬁcantly increased
(p¼0.033, ﬁgure 7C). Within the cohort of patients with IPF
(online supplement), serum TRAIL levels were signiﬁcantly
correlated with predicted TLco (p¼0.046, ﬁgure 8), although the
magnitude of the correlation was not large. There was no rela-
tionship identiﬁed between forced vital capacity (% predicted)
and serum TRAIL levels and no correlation of serum OPG levels
with any of these parameters (data not shown).
DISCUSSION
Neutrophils are thought to play an important role in the path-
ogenesis of pulmonary ﬁbrosis. Accumulation of neutrophils and
increased release of neutrophil chemotactic factors are observed
Figure 2 TUNEL-positive apoptotic events are reduced in tumour
necrosis factor-related apoptosis-inducing ligand (TRAIL)-deficient mice.
Representative TUNEL-stained lung tissue sections from wild-type (A)
and TRAIL/ mice (B) at day 23 after bleomycin instillation. Apoptotic
events are visible as brown-stained cells. (C) Numbers of TUNEL-
positive cells per high-power field (HPF) were significantly higher in wild-
type than in TRAIL/ mice (**p<0.0001, n¼3 mice per group,
counting 10 random fields per section).
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Figure 3 Neutrophil apoptosis in bronchoalveolar lavage (BAL) fluid
following intratracheal administration of bleomycin in wild-type and
tumour necrosis factor-related apoptosis-inducing ligand (TRAIL)-
deficient mice. The percentage of BAL fluid neutrophils with
morphological appearances of apoptosis was assessed at day 3, 7, 16
and 23 after bleomycin instillation. (A) At time points up to day 7, <4%
of neutrophils were apoptotic in both wild-type (solid line) and TRAIL/
mice (dashed line). At days 7 and 16, the percentage of apoptotic
neutrophils was increased in both populations, but there was
a significantly lower proportion of apoptotic neutrophils in TRAIL/
mice (**p¼0.0003 at day 7 and *p¼0.012 at day 16). (B) Total numbers
of apoptotic neutrophils were also significantly reduced in TRAIL/
mice (*p¼0.0316 at day 7).
Thorax 2012;67:796e803. doi:10.1136/thoraxjnl-2011-200863 799
Interstitial lung disease
 group.bmj.com on October 10, 2014 - Published by thorax.bmj.comDownloaded from 
in patients with a variety of causes of pulmonary ﬁbrosis,
including IPF.4 21 Neutrophil-dependent, T-cell independent
mechanisms make an important contribution to collagen
deposition in several murine models of pulmonary ﬁbrosis while
factors which reduce neutrophil accumulation and production of
neutrophil chemotactic factors reduce collagen deposition.22e25
Thus accumulation of neutrophils, which can perpetuate
pulmonary inﬂammation through the release of matrix metal-
loproteinases and serine proteases, can enhance pulmonary
ﬁbrosis.8 26 Conversely, compounds such as cyclin-dependant
kinase inhibitors that accelerate neutrophil apoptosis reduce
lung ﬁbrosis.13
We examined the role of TRAIL in chronic inﬂammation in
the lung using the well established bleomycin model. This model
reproduces many of the histological features of IPF and is asso-
ciated with recruitment of inﬂammatory cells, including
neutrophils, into the injured lung during the ﬁrst 7 days, with
ﬁbrotic change and deposition of matrix occurring up to day
35.27 Assessment of the inﬂammatory responses in wild-type
and TRAIL/ mice revealed TRAIL deﬁciency resulting in
increased BAL neutrophilia and reduced neutrophil apoptosis.
The total number of neutrophils present in BAL in the bleo-
mycin-treated wild-type mice was in keeping with previous
data.8 The recruitment of neutrophils to the lung cannot be
directly measured in murine models but the two strains showed
equivalent cell numbers at day 3, which subsequently diverged,
suggesting no difference in rates of initial recruitment. The data
could reﬂect ongoing neutrophil recruitment at later time points
in TRAIL/ mice but also suggest a contribution of delayed
apoptosis and clearance of these cells. Delay of apoptosis is
supported both by the ﬁnding of reduced TUNEL-positive
events in inﬂammatory cells (ﬁgure 2) and of reduced numbers
of apoptotic neutrophils in BAL (ﬁgure 3) and by our previous
data in lipopolysaccharide (LPS)-mediated lung injury.15
TRAIL-deﬁcient mice showed biochemical evidence of
increased collagen deposition. In both the bleomycin model and
human pulmonary ﬁbrosis tissue, there is increased deposition of
collagen and other molecules of the extracellular matrix by lung
ﬁbroblasts.8 Previous work by Yurovsky showed TRAIL induces
apoptosis of primary lung ﬁbroblasts derived from patients with
IPF.17 The increased lung collagen we observed in the absence of
TRAIL could, therefore, result from the lack of its pro-apoptotic
effects on pulmonary ﬁbroblasts, and/or the increased inﬂam-
matory drive to ﬁbroproliferation consequent upon increased
numbers of neutrophils.
TRAIL is widely expressed on leucocyte populations and, in the
normal human lung, TRAIL expression has been detected on
alveolar septa, bronchial epithelium and vascular endothelium.9 28
In bleomycin-treated wild-type mice, TRAIL was also detected
in a population of CD3-positive, peribronchial inﬂammatory
cells with the appearances of bronchus associated lymphoid
tissue and in galectin-3-positive air-space cells with the
Figure 4 Lung collagen accumulation in response to bleomycin is
increased in tumour necrosis factor-related apoptosis-inducing ligand
(TRAIL)-deficient mice. (AeC) Representative lung tissue sections
stained with Masson’s Trichrome from wild-type mice at day 7 and 23
after saline and bleomycin instillations. (A) Lung architecture was normal
in TRAIL/ mice given saline. (B) and (C) Extensive patchy fibrotic foci
with increased deposition of collagen were seen in wild-type mice given
bleomycin at day 7 and 23, respectively. (D) Total lung collagen as
measured by reverse phase high-performance liquid chromatography
quantitation of lung hydroxyproline in acid hydrolysates of pulverised
lung. Data represent the mean 6 SEM of values obtained in groups of
five mice. Wild-type and TRAIL/ mice instilled with saline had similar
collagen levels in the lungs. Wild-type mice instilled with bleomycin had
a significant increase in collagen compared with the saline control
(*p¼0.0033). TRAIL/ mice had a significant increase in collagen
compared with wild-type mice instilled with bleomycin (**p¼0.005) and
with saline controls (**p¼0.0004).
[Continued]
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characteristic appearance of alveolar macrophages. These ﬁnd-
ings were in keeping with BAL analysis in which macrophages
and lymphocytes were found to express TRAIL by ﬂow
cytometry (data not shown). Macrophage expression of death
receptor ligands has been shown to regulate apoptosis induction
in a variety of inﬂammatory cells. A role for macrophage Fas
ligand (FasL) induction of target cell killing has been described
and for TNFa acting in concert with integrins in the macro-
phage induction of apoptosis in neutrophils.29 30 We did not
detect neutrophil expression of TRAIL in our experiments, in
keeping with other recent data.31 The distribution of TRAIL
expression in wild-type mice following bleomycin lung injury,
with ongoing expression on epithelial cells but upregulated
expression on inﬂammatory cells, is very different from that in
control samples and in LPS-mediated lung injury or allergen
challenge models in which TRAIL expression is predominantly
on the airway epithelium.15 19 In a recently described model of
inﬂuenza-mediated inﬂammatory lung disease, TRAIL was
expressed on alveolar macrophages and also on a small propor-
tion of natural killer cells in BAL.31 Our data suggest that
macrophage-expressed and possibly lymphocyte-expressed
TRAIL could play an important role in regulating the inﬂam-
matory response in chronic pulmonary inﬂammation.
TRAIL is not the only death receptor ligand shown to induce
apoptosis of inﬂammatory leucocytes. FasL and TNFa have well
characterised roles in acceleration of neutrophil apoptosis, but
Figure 5 Tumour necrosis factor-
related apoptosis-inducing ligand
(TRAIL) expression localises to
bronchus associated lymphoid tissue
(BALT) and alveolar macrophages. Lung
sections 16 days after bleomycin
instillation were immunohistochemically
stained for TRAIL. (A) Lung section
demonstrating the presence of alveolar
macrophages and BALT tissue and
absence of specific TRAIL
immunostaining in a TRAIL/ mouse.
(B) and (C) Lung sections
(representative of sections from five
mice) demonstrating TRAIL expression
localised to epithelium and BALT in
a wild-type mouse. (D) Lung section
demonstrating TRAIL expressing
alveolar macrophages in a wild-type
mouse.
Figure 6 Immunohistochemical
localisation of tumour necrosis factor-
related apoptosis-inducing ligand
(TRAIL) in human lung specimens.
Immunostaining for TRAIL on
representative lung tissue sections from
human lung material. (A) and (B)
Intense immunostaining for TRAIL in
control lung was associated with
macrophages and alveolar epithelium.
Representative images are shown from
lung sections of three individuals. (CeF)
Analysis of lung tissue from patients
with idiopathic pulmonary fibrosis.
Representative images are shown from
lung sections of five individuals. (C, D)
Areas of lung with relatively normal
architecture showed TRAIL staining
similar to that from control lung
samples whereas matched samples
from fibrotic areas of the same individuals
(E, F) demonstrated almost no positive
immunostaining for TRAIL. Scale bars for
panels (A), (C) and (E) represent 100 mm
and for (B), (D) and (F) 50 mm.
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each also has signiﬁcant proinﬂammatory effects. TRAIL mostly
induces apoptosis of transformed cells, although effects on some
primary cell types are described.9 We previously showed TRAIL
had no chemotactic effects in human neutrophils in vitro but did
accelerate neutrophil apoptosis via ligation of the TRAIL-R2
receptor.12 The TRAIL system has since been implicated in the
elimination of senescent circulating neutrophils, suggesting
a role in physiologic regulation of neutrophil lifespan. In addi-
tion, we recently found TRAIL-deﬁcient mice have an enhanced
inﬂammatory response to LPS in vivo.14 15 The majority of
primary cell types, although not all, are resistant to TRAIL, in
part due to expression of cell surface decoy receptors TRAIL-R3
and TRAIL-R4, reducing the likelihood of unwanted cytotox-
icity in other cell types with TRAIL treatment in vivo.9 In
contrast, FasL induces apoptosis of bronchial epithelial cells and
pulmonary overexpression of TNFa induces chronic pulmonary
inﬂammation and ﬁbrosis.32 33
Recent work in a murine model of asthma showed increased
pulmonary epithelial expression of TRAIL and that inhibition of
TRAIL function attenuated allergic inﬂammation.19 In contrast,
we found the absence of TRAIL is associated with enhanced
inﬂammation in the lung and that TRAIL is expressed on
macrophage and lymphoid cells. Moreover, absence of TRAIL
results in more severe inﬂammation and ﬁbrosis, suggesting this
ligand may have a role in ameliorating non-allergic inﬂamma-
tion. In keeping with this, recent studies of TRAIL-R-deﬁcient
mice showed development of severe pneumonitis following
ionising radiation that was absent from wild-type mice.34
We show there may be a relative paucity of TRAIL expression
in the ﬁbrotic regions of interstitial lung disease in man. Lung
samples from patients with IPF showed low levels of TRAIL
expression in densely ﬁbrosed areas, with relative preservation of
TRAIL expression in more histologically normal areas. Circu-
lating levels of soluble TRAIL were lower in patients with IPF
than in controls, whereas levels of the soluble receptor, OPG,
were unchanged. The magnitude of difference seen in TRAIL
levels, although relatively small, was comparable to other
studies using the same ELISA and equivalent to the changes seen
in patients with atherosclerosis compared with healthy
controls, where lower levels of TRAIL have been shown to be of
prognostic signiﬁcance.20 35
The biological roles of TRAIL in human IPF clearly require
further exploration. In the bleomycin model, deﬁciency of
TRAIL leads to increased inﬂammation and collagen deposition,
suggesting TRAIL expression by leucocytes and/or tissue cells
acts to limit these features of disease and thus might act as
a disease modiﬁer, inﬂuencing disease progression. TRAIL also
has possible utility as a biomarker of disease progression in IPF,
which could be addressed in longitudinal studies. Whether
TRAIL has a role in susceptibility to disease is unknown,
although functional genetic polymorphisms of TRAIL and its
receptors exist and could be studied in patients with IPF and
control populations. It is also conceivable that treatment with
exogenous TRAIL might have a beneﬁcial anti-inﬂammatory
and antiﬁbrotic effect in IPF. Forms of recombinant TRAIL and
TRAIL-R2 agonistic antibodies are in clinical trials in a range of
malignant diseases and could be considered for a non-malignant
disease, such as IPF, with an equally poor prognosis.11
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Figure 7 Serum levels of tumour necrosis factor-related apoptosis-
inducing ligand (TRAIL) and its soluble receptor osteoprotegerin (OPG) in
patients with idiopathic pulmonary fibrosis (IPF) and matched controls.
Serum levels of (A) TRAIL and (B) OPG were measured by ELISA in
patients with IPF and matched controls. Data was also expressed as (C)
the ratio of OPG to TRAIL. TRAIL levels were significantly reduced in
patients with IPF (**p¼0.002) and the OPG:TRAIL ratio correspondingly
increased (*p¼0.033).
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Figure 8 Serum levels of tumour necrosis factor-related apoptosis-
inducing ligand (TRAIL) correlate with TLco values. Serum TRAIL,
measured at time of clinical presentation with idiopathic pulmonary
fibrosis (IPF), was significantly correlated with TLco (% predicted) at
time of diagnosis (r2¼0.149, p¼0.046).
802 Thorax 2012;67:796e803. doi:10.1136/thoraxjnl-2011-200863
Interstitial lung disease
 group.bmj.com on October 10, 2014 - Published by thorax.bmj.comDownloaded from 
Acknowledgements We thank Amgen Inc (Seattle, Washington, USA) and Dr
Mark Smyth for the gift of TRAIL-deficient mice.
Contributors EEMG performed the bulk of experimental work, with HM, VS, AART,
SW and DD involved in establishing and conducting in vivo experiments and PM and
RCC in designing and performing collagen assays. AL, NA and SSC performed and
interpreted immunohistochemistry. MKBW, SR, IS, RCC and DD were involved in
multiple aspects of experimental design and, together with EMG, wrote the
manuscript. All authors reviewed and commented upon the manuscript.
Funding This work was funded by a Wellcome Trust Clinical Research Training
Fellowship to EMcG (075776), by the NIHR Cardiovascular Biomedical Research Unit
Sheffield (IS and MKBW) and by generous donations in memory of Mrs Eileen Hawley,
Mrs Susan Utley and Mr Derrick Woolley. AL holds an MRC Career Development
Award Fellowship (G0800318), SRW is a Wellcome Clinician Scientist Fellow
(078244), SAR is an MRC Senior Clinical Fellow (G0701932) and DHD a Wellcome
Trust Senior Clinical Fellow (076945).
Competing interests None.
Ethics approval Ethics approval was provided by Papworth Hospital Ethics
Committee and South Sheffield Research Ethics Committee.
Provenance and peer review Not commissioned; externally peer reviewed.
REFERENCES
1. Bradley B, Branley HM, Egan JJ, et al. Interstitial lung disease guideline:
the British Thoracic Society in collaboration with the Thoracic Society of
Australia and New Zealand and the Irish Thoracic Society. Thorax
2008;63(Suppl 5):v1e58.
2. Selman M, King TE, Pardo A. Idiopathic pulmonary fibrosis: prevailing and evolving
hypotheses about its pathogenesis and implications for therapy. Ann Intern Med
2001;134:136e51.
3. Crystal RG, Bitterman PB, Rennard SI, et al. Interstitial lung diseases of unknown
cause. Disorders characterized by chronic inflammation of the lower respiratory tract
(first of two parts). N Engl J Med 1984;310:154e66.
4. Hunninghake GW, Gadek JE, Lawley TJ, et al. Mechanisms of neutrophil
accumulation in the lungs of patients with idiopathic pulmonary fibrosis. J Clin Invest
1981;68:259e69.
5. Kinder BW, Brown KK, Schwarz MI, et al. Baseline BAL neutrophilia predicts early
mortality in idiopathic pulmonary fibrosis. Chest 2008;133:226e32.
6. Beeh KM, Beier J, Kornmann O, et al. Neutrophilic inflammation in induced sputum
of patients with idiopathic pulmonary fibrosis. Sarcoidosis Vasc Diffuse Lung Dis
2003;20:138e43.
7. Oikonomou N, Thanasopoulou A, Tzouvelekis A, et al. Gelsolin expression is
necessary for the development of modelled pulmonary inflammation and fibrosis.
Thorax 2009;64:467e75.
8. Chua F, Dunsmore SE, Clingen PH, et al. Mice lacking neutrophil elastase
are resistant to bleomycin-induced pulmonary fibrosis. Am J Pathol
2007;170:65e74.
9. Sheridan JP, Marsters SA, Pitti RM, et al. Control of TRAIL-induced apoptosis by
a family of signaling and decoy receptors. Science 1997;277:818e21.
10. Wu GS, Burns TF, Zhan Y, et al. Molecular cloning and functional analysis of the
mouse homologue of the killer/DR5 tumor necrosis factor-related apoptosis-inducing
ligand (TRAIL) death receptor. Cancer Res 1999;59:2770e5.
11. Bellail AC, Qi L, Mulligan P, et al. TRAIL agonists on clinical trials for cancer therapy:
the promises and the challenges. Rev Recent Clin Trials 2009;4:34e41.
12. Renshaw SA, Parmar JS, Singleton V, et al. Acceleration of human neutrophil
apoptosis by TRAIL. J Immunol 2003;170:1027e33.
13. Rossi AG, Sawatzky DA, Walker A, et al. Cyclin-dependent kinase inhibitors enhance
the resolution of inflammation by promoting inflammatory cell apoptosis. Nat Med
2006;12:1056e64.
14. Lum JJ, Bren G, McClure R, et al. Elimination of senescent neutrophils by TNF-
related apoptosis-inducing ligand. J Immunol 2005;175:1232e8.
15. McGrath EE, Marriott HM, Lawrie A, et al. TNF-related apoptosis inducing ligand
(TRAIL) regulates inflammatory neutrophil apoptosis and enhances resolution of
inflammation. J Leukoc Biol 2011;90:855e65.
16. Taimr P, Higuchi H, Kocova E, et al. Activated stellate cells express the TRAIL
receptor-2/death receptor-5 and undergo TRAIL-mediated apoptosis. Hepatology
2003;37:87e95.
17. Yurovsky VV. Tumor necrosis factor-related apoptosis-inducing ligand enhances
collagen production by human lung fibroblasts. Am J Respir Cell Mol Biol
2003;28:225e31.
18. Howell DC, Johns RH, Lasky JA, et al. Absence of proteinase-activated receptor-1
signaling affords protection from bleomycin-induced lung inflammation and fibrosis.
Am J Pathol 2005;166:1353e65.
19. Weckmann M, Collison A, Simpson JL, et al. Critical link between TRAIL and CCL20
for the activation of TH2 cells and the expression of allergic airway disease. Nat Med
2007;13:1308e15.
20. Schoppet M, Sattler AM, Schaefer JR, et al. Osteoprotegerin (OPG) and tumor
necrosis factor-related apoptosis-inducing ligand (TRAIL) levels in atherosclerosis.
Atherosclerosis 2006;184:446e7.
21. Pardo A, Barrios R, Gaxiola M, et al. Increase of lung neutrophils in hypersensitivity
pneumonitis is associated with lung fibrosis. Am J Respir Crit Care Med
2000;161:1698e704.
22. Keane MP, Belperio JA, Moore TA, et al. Neutralization of the CXC chemokine,
macrophage inflammatory protein-2, attenuates bleomycin-induced pulmonary
fibrosis. J Immunol 1999;162:5511e18.
23. Christensen PJ, Goodman RE, Pastoriza L, et al. Induction of lung fibrosis in the
mouse by intratracheal instillation of fluorescein isothiocyanate is not T-cell-
dependent. Am J Pathol 1999;155:1773e9.
24. Dona M, Dell’Aica I, Calabrese F, et al. Neutrophil restraint by green tea: inhibition of
inflammation, associated angiogenesis, and pulmonary fibrosis. J Immunol
2003;170:4335e41.
25. Russo RC, Guabiraba R, Garcia CC, et al. Role of the chemokine receptor CXCR2 in
bleomycin-induced pulmonary inflammation and fibrosis. Am J Respir Cell Mol Biol
2009;40:410e21.
26. Gaggar A, Jackson PL, Noerager BD, et al. A novel proteolytic cascade generates an
extracellular matrix-derived chemoattractant in chronic neutrophilic inflammation. J
Immunol 2008;180:5662e9.
27. Moeller A, Ask K, Warburton D, et al. The bleomycin animal model: a useful tool to
investigate treatment options for idiopathic pulmonary fibrosis? Int J Biochem Cell
Biol 2008;40:362e82.
28. Spierings DC, de Vries EG, Vellenga E, et al. Tissue distribution of the death ligand
TRAIL and its receptors. J Histochem Cytochem 2004;52:821e31.
29. Dockrell DH, Lee M, Lynch DH, et al. Immune-mediated phagocytosis and killing of
Streptococcus pneumoniae are associated with direct and bystander macrophage
apoptosis. J Infect Dis 2001;184:713e22.
30. Meszaros AJ, Reichner JS, Albina JE. Macrophage-induced neutrophil apoptosis. J
Immunol 2000;165:435e41.
31. Herold S, Steinmueller M, von Wulffen W, et al. Lung epithelial apoptosis in
influenza virus pneumonia: the role of macrophage-expressed TNF-related apoptosis-
inducing ligand. J Exp Med 2008;205:3065e77.
32. Nakamura M, Matute-Bello G, Liles WC, et al. Differential response of human lung
epithelial cells to Fas-induced apoptosis. Am J Pathol 2004;164:1949e58.
33. Miyazaki Y, Araki K, Vesin C, et al. Expression of a tumor necrosis factor-alpha
transgene in murine lung causes lymphocytic and fibrosing alveolitis. A mouse model
of progressive pulmonary fibrosis. J Clin Invest 1995;96:250e9.
34. Finnberg N, Klein-Szanto AJ, El-Deiry WS. TRAIL-R deficiency in mice promotes
susceptibility to chronic inflammation and tumorigenesis. J Clin Invest
2008;118:111e23.
35. Michowitz Y, Goldstein E, Roth A, et al. The involvement of tumor necrosis factor-
related apoptosis-inducing ligand (TRAIL) in atherosclerosis. J Am Coll Cardiol
2005;45:1018e24.
PAGE fraction trail=7.75
Thorax 2012;67:796e803. doi:10.1136/thoraxjnl-2011-200863 803
Interstitial lung disease
 group.bmj.com on October 10, 2014 - Published by thorax.bmj.comDownloaded from 
doi: 10.1136/thoraxjnl-2011-200863
 2012 67: 796-803 originally published online April 11, 2012Thorax
 
Emmet E McGrath, Allan Lawrie, Helen M Marriott, et al.
 
injury and fibrosis
apoptosis-inducing ligand exacerbates lung 
Deficiency of tumour necrosis factor-related
 http://thorax.bmj.com/content/67/9/796.full.html
Updated information and services can be found at: 
These include:
Data Supplement
 http://thorax.bmj.com/content/suppl/2012/04/10/thoraxjnl-2011-200863.DC1.html
"Supplementary Data"
References
 http://thorax.bmj.com/content/67/9/796.full.html#related-urls
Article cited in: 
 
 http://thorax.bmj.com/content/67/9/796.full.html#ref-list-1
This article cites 35 articles, 14 of which can be accessed free at:
Open Access
http://creativecommons.org/licenses/by-nc/2.0/legalcode.
http://creativecommons.org/licenses/by-nc/2.0/ and 
compliance with the license. See:
work is properly cited, the use is non commercial and is otherwise in 
use, distribution, and reproduction in any medium, provided the original
Creative Commons Attribution Non-commercial License, which permits 
This is an open-access article distributed under the terms of the
service
Email alerting
the box at the top right corner of the online article.
Receive free email alerts when new articles cite this article. Sign up in
Collections
Topic
 (412 articles)Interstitial lung disease   
 (867 articles)Inflammation   
 (157 articles)Chemotherapy   
 (119 articles)Open access   
 
Articles on similar topics can be found in the following collections
 http://group.bmj.com/group/rights-licensing/permissions
To request permissions go to:
 http://journals.bmj.com/cgi/reprintform
To order reprints go to:
 http://group.bmj.com/subscribe/
To subscribe to BMJ go to:
 group.bmj.com on October 10, 2014 - Published by thorax.bmj.comDownloaded from 
Notes
 http://group.bmj.com/group/rights-licensing/permissions
To request permissions go to:
 http://journals.bmj.com/cgi/reprintform
To order reprints go to:
 http://group.bmj.com/subscribe/
To subscribe to BMJ go to:
 group.bmj.com on October 10, 2014 - Published by thorax.bmj.comDownloaded from 
